{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:55:16Z","timestamp":1781762116155,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the value of nucleic acid-based matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in identifying mycobacterial species and detecting drug resistance in patients with retreatment pulmonary tuberculosis (TB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical data of 100 patients with retreatment pulmonary TB treated at Wenzhou Central Hospital between 1 June 2022 and 31 December 2023 were retrospectively collected and analyzed. Respiratory secretions were examined using BACTEC MGIT 960 Rapid Liquid Culture (MGIT 960 culture), drug-sensitive gene chip strain identification and nucleic acid-based MALDI-TOF MS assay (MassARRAY\u00ae system). Unlike traditional protein-based MALDI-TOF MS, this nucleic acid-based approach detects specific gene mutations associated with drug resistance. The results of the MGIT 960 culture and drug resistance testing served as the benchmark for evaluating the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the MALDI-TOF MS assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB) detection, compared with the MGIT 960 culture, the nucleic acid-based MALDI-TOF MS assay demonstrated a sensitivity of 97.01% (65\/67), specificity of 63.64% (21\/33), PPV of 84.42% (65\/77) and NPV of 91.30% (21\/23), with a concordance of 86.00% and a kappa value of 0.619. The difference in detection results between the two methods was statistically significant (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f15.625,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). For drug-resistance detection in the 34 MTB-positive cases with both methods, concordance with MGIT 960 was 97% for rifampicin (97% sensitivity, 100% specificity) and 88% for isoniazid (86% sensitivity, 100% specificity), with overall\n                      <jats:italic>\u03ba<\/jats:italic>\n                      \u202f=\u202f0.83 across first- and second-line drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The nucleic acid-based MALDI-TOF MS assay demonstrates promising performance in rapidly identifying MTB and detecting drug resistance, serving as a valuable complementary tool for rapid clinical diagnosis and personalized medication guidance in patients with retreatment TB. The detection of non-tuberculous mycobacteria requires further validation with larger sample sizes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1694247","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:36:08Z","timestamp":1781760968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of nucleic acid-based matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry for rapid identification of Mycobacterium tuberculosis and drug resistance in patients with retreatment tuberculosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiajun","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Dingli Clinical College of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Dingli Clinical College of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liufeng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Postgraduate Training Base Alliance of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiduo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Dingli Clinical College of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Dingli Clinical College of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Postgraduate Training Base Alliance of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Postgraduate Training Base Alliance of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochao","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Dingli Clinical College of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Infection, Wenzhou Central Hospital, Dingli Clinical College of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e070143","DOI":"10.1136\/bmjopen-2022-070143","article-title":"Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis","volume":"13","author":"Alemu","year":"2023","journal-title":"BMJ Open"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3969\/j.issn.1000-6621.2019.10.001","article-title":"Guidelines for chemotherapy of drug-resistant tuberculosis (2019 abbreviated version)","volume":"1","year":"2019","journal-title":"Chin. J. Antituberc."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e02074","DOI":"10.1128\/AAC.02074-18","article-title":"Role of therapeutic drug monitoring in treatment optimization in tuberculosis and diabetes mellitus comorbidity","volume":"63","author":"Dekkers","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5588\/pha.22.0047","article-title":"Increase in rifampicin resistance among people previously treated for TB","volume":"13","author":"Izudi","year":"2023","journal-title":"Public Health Action."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.cmi.2023.07.014","article-title":"Update on the diagnosis of tuberculosis","volume":"30","author":"Kontsevaya","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1079184","DOI":"10.3389\/fcimb.2022.1079184","article-title":"Performance evaluation and clinical validation of optimized nucleotide MALDI-TOF-MS for mycobacterial identification","volume":"12","author":"Li","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.19982\/j.issn.1000-6621.20230113","article-title":"Expert consensus on the clinical application of nucleic acid MALDI-TOF MS technique in the diagnosis of tuberculosis and non-tuberculosis mycobacteriosis","volume":"45","author":"Liang","year":"2023","journal-title":"Chin. J. Antituberc."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0154524","DOI":"10.1128\/spectrum.01545-24","article-title":"Application value of nucleic acid MALDI-TOF MS in mycobacterial species identification and drug resistance detection in Mycobacterium tuberculosis","volume":"13","author":"Liu","year":"2025","journal-title":"Microbiol. Spectrum"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1064512","DOI":"10.3389\/fpubh.2023.1064512","article-title":"Biological interpretation of the sporadic sputum smear-positive-culture-negative outcome for patients with tuberculosis undertaking treatments","volume":"11","author":"Luo","year":"2023","journal-title":"Front. Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/resp.13393","article-title":"Drug resistance mechanisms and drug susceptibility testing for tuberculosis","volume":"23","author":"Miotto","year":"2018","journal-title":"Respirology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/5584_2017_26","article-title":"Identification of Mycobacterium species by MALDI-TOF mass spectrometry","volume":"1021","author":"Neuschlova","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10096-023-04700-y","article-title":"Diagnostic efficacy of an optimized nucleotide MALDI-TOF-MS assay for anti-tuberculosis drug resistance detection","volume":"43","author":"Ou","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3390\/genes12122003","article-title":"The neglected contribution of streptomycin to the tuberculosis drug resistance problem","volume":"12","author":"Rocha","year":"2021","journal-title":"Genes (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0119628","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"Seifert","year":"2015","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"116686","DOI":"10.1016\/j.diagmicrobio.2025.116686","article-title":"Clinical application of time-of-flight mass spectrometry nucleic acid detection technology in diagnosis of drug-resistant pulmonary tuberculosis","volume":"111","author":"Shi","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"41486","DOI":"10.1038\/srep41486","article-title":"Rapid sputum multiplex detection of the M. tuberculosis complex (MTBC) and resistance mutations for eight antibiotics by nucleotide MALDI-TOF MS","volume":"7","author":"Su","year":"2017","journal-title":"Sci. Rep."},{"key":"ref18","year":"2021"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijid.2022.04.061","article-title":"Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI-TOF-MS","volume":"121","author":"Wu","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12879-020-4758-9","article-title":"Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China","volume":"20","author":"Xia","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e0048325","DOI":"10.1128\/spectrum.00483-25","article-title":"Rapid detection of rifampin resistance in Mycobacterium tuberculosis using nucleotide MALDI-TOF MS: a comparative study with phenotypic drug susceptibility testing and DNA sequencing","volume":"13","author":"Zhang","year":"2025","journal-title":"Microbiol. Spectrum"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1694247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:36:09Z","timestamp":1781760969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1694247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":21,"alternative-id":["10.3389\/fmicb.2026.1694247"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1694247","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1694247"}}